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Abstract
Introduction: Gastric tumors in patients affected by neurofibromatosis type 1 are usually carcinoids or stromal
tumors, and rarely adenocarcinomas.
Case presentation: We report a case of an adenocarcinoma of the stomach in a 53-year-old Japanese man with
neurofibromatosis type 1. An abdominal computed tomography scan and ultrasonography showed tumors in his
liver. Gastric fibroscopy revealed a Borrmann type III tumor on his cardia that had spread to his esophagus and was
highly suspicious for malignancy. Multiple biopsies showed an adenocarcinoma of the stomach, which was
evaluated as gastric cancer, stage IV. Chemotherapy with TS-1 was performed. Our patient died four weeks after
initial admission. Histological examination of a liver needle biopsy showed metastatic adenocarcinoma in his liver.
Conclusion: To the best of our knowledge, high serum levels of a-fetoprotein, carcinoembryonic antigen, and
carbohydrate antigen 72-4, resulting from gastric adenocarcinoma, have not been reported previously in a patient
with neurofibromatosis type 1. We report this rare case along with a review of the literature.
Introduction
Neurofibromatosis type 1 (NF-1), or von Recklinghausen’s
disease, is an autosomal dominant disorder characterized
by cutaneous hyperpigmentation and multiple neurofibro-
mas. The symptoms are café-au-lait spots, cutaneous neu-
rofibromas and neoplasms of the peripheral or central
nervous system. The genetic basis of the disease is a muta-
tion on chromosome 17q11.2 [1]; however, no frequently
recurring mutation has been identified. Malignancies are
found in 3% to 15% of patients [2]. Occasionally reported
in primary neoplasms, malignancies are most often asso-
ciated with the peripheral or central nervous system.
There have been reports of primary epithelial tumors of
the gastrointestinal (GI) tract such as esophageal, gastric,
small intestinal and colonic tumors [1,3], but GI involve-
ment is rare [2]. We report a rare case of advanced gastric
cancer in a patient with NF-1.
Case presentation
A 53-year-old Japanese man affected by NF-1 presented
with a three-week history of jaundice, upper abdominal
discomfort, dysphagia and loss of appetite (Figure 1A). His
mother had a history of neurofibromatosis. Upon physical
examination, a smooth mass, with its largest dimension
measuring 20 cm, was palpated in his right upper abdo-
men. On admission, laboratory findings revealed leukocy-
tosis, with a white blood cell count of 12,200/mm
3;
aspartate aminotransferase, 75 U/L; alanine aminotransfer-
ase, 75 U/L; alkaline phosphates 1913 U/L; g-glutamyl
transferase, 960 U/L; total protein, 7.4 g/dL; and total bilir-
ubin, 4.4 mg/dL. His C-reactive protein level was 9.3 mg/
mL (normal range, 0.5 mg/mL to 0.8 mg/mL). His serum
level of carcinoembryonic antigen (CEA) was extremely
high at 3050 ng/mL (cutoff, 2.5 ng/mL), and his a-fetopro-
tein (AFP) level was 812 ng/mL (cutoff, 10 ng/mL). The
carbohydrate antigen (CA) 72-4 was also high at 180 U/mL
(cutoff, 8.0 U/mL); CA 19-9 was normal at 16 U/mL (cut-
off, 37 U/mL). An upper GI barium study showed a 5.0 cm
filling defect on his cardia that extended to his lower eso-
phagus. An abdominal computerized tomography (CT)
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lymph node enlargement was identified (Figure 1B). Gas-
troendoscopic examination revealed a tumor with a 6 cm
diameter on the esophagogastric junction, which was
spreading to his esophagus (Figures 2A and 2B). Multiple
biopsies showed moderately differentiated tubular adeno-
carcinoma of the stomach at stage IV (Figure 3A). An
immunohistochemical study showed that CEA-positive
and AFP-negative cells were present in the tumor (Figures
3B and 3C). Our patient was administered palliative che-
motherapy and treated with TS-1 (tegafur, gimeracil, otera-
cil potassium). Our patient died due to liver failure a
month after initial admission. A pathological review of
necropsy specimens of his liver lesions showed moderately
differentiated tubular adenocarcinoma (Figure 4A). An
immunohistochemical study showed that CEA-positive
and AFP-negative cells were present in the metastatic liver
tumor resembling the gastric lesion (Figures 4B and 4C).
Figure 1 Examinations on admission. (A) Multiple discrete cutaneous neurofibromas and café au lait spots located on his abdominal wall. The
abdominal wall was swollen with ascites. (B) An abdominal CT study showed multiple liver lesions and ascites.
Figure 2 Gastroendoscopic examination. (A) A tumor was revealed on the cardia and extending to (B) his esophagus.
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NF-1, or von Recklinghausen’s disease, was first described
in 1882. It is a relatively common autosomal hereditary
dominant disorder that equally involves men and woman
and has variable expression, a frequency of one per 3000
births, and a high rate of new mutations [4]. The genetic
basis of the disease is a mutation located on chromosome
17q11.2 [1]. NF-1 is characterized by brown skin pigmen-
tation (’café au lait’ spots), cutaneous neurofibromas and
neoplasms of the peripheral or central nervous system.
The association between NF-1 and tumors of neurogenic
and neuroendocrine origin, such as meningiomas, gliomas
and pheochromocytomas, is well known. Malignancies are
found in 3% to 5% of patients. GI involvement is present
in approximately a quarter of cases [2]. GI involvement in
NF-1 commonly occurs in four principal forms: hyperpla-
sia of the gut neural tissue, multiple GI stromal tumors
(GISTs), duodenal or periampullary endocrine tumors and
a miscellaneous group of other tumors. GISTs are the
most common of these forms [1]. Although there have
Figure 3 Immunohistochemical study. (A) Multiple biopsies showed a moderately differentiated tubular adenocarcinoma (×100). (B)
Immunohistochemical determination of CEA in the area of the adenocarcinoma was positive (×100). (C) Immunohistochemical determination of
AFP in the area of the adenocarcinoma was negative (×100).
Figure 4 Pathological review. (A) Necropsy specimens of the liver showed moderately differentiated tubular adenocarcinoma (×100). (B)
Immunohistochemical determination of CEA was positive (×100). (C) Immunohistochemical determination of AFP was negative (×100).
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complicating peripheral neurofibromatosis [1,3], few cases
have explored the association of primary infiltrating ade-
nocarcinoma of the stomach [5]. It has been indicated that
loss of function of the NF-1 gene results in peripheral neu-
rofibromatosis [6], but no definite reasons have been cited
for the high incidence of primary malignant tumors
in these patients. The NF-1 gene and the p53 tumor sup-
pressor gene are both located on chromosome 17 (6),
suggesting that the p53 gene is mutated in several NF-1-
associated tumors [7]. Researchers have sought to deter-
m i n et h er o l eo fp53 tumor suppressor genes in the
etiopathogenesis of NF-1-associated malignant primary
tumors. In a recent study, a germline NF-1 nonsense
mutation in exon 37 was detected by DNA sequence ana-
lysis, showing that the GI tumor arose through NF-1 gene
inactivation [8]. The NF-1 gene product, neurofibromin,
contains a guanosine 5’-triphosphate (GPT)ase-activating
protein-related domain that is able to down-regulate
p21ras by stimulating its intrinsic GPTase. Because
p21ras-GPT is a major regulator of growth and differentia-
tion, mutant neurofibromins resulting from somatic muta-
tions in the NF-1 gene might interfere with ras signaling
pathways and contribute to the development of tumors
[9]. These results suggest a causal association between
NF-1 and the development of gastric cancer in our case.
AFP- positive cases have been found among disorders
other than hepatocellular carcinoma, such as hepatitis,
liver cirrhosis and metastatic cancer of the liver. Addi-
tionally, elevated levels of serum AFP have been reported
to occur with several tumor types other than hepatocellu-
lar carcinoma and embryonic cell carcinoma [10]. These
elevated levels have largely been associated with neo-
plasms of the GI tract [11]. In the GI tract, an elevation
of the serum AFP level was reported in 1.3% to 15% of
gastric cancers [10]. The authors described AFP-produ-
cing gastric adenocarcinomas with a high serum AFP
level and synchronous hepatic metastasis. Gastric cancers
that secrete AFP are rare. The first case was described in
1970 [11]. AFP-secreting gastric cancers occur with a fre-
quency of 2% to 6%. The prognosis of these cases tends
to be poor with a high frequency of hepatic metastasis at
presentation. Liver metastasis has been reported to occur
in 70% to 80% of cases. Our patient had an elevated
serum AFP level and a gastric cancer with liver metasta-
sis without viral hepatitis or liver cirrhosis; however, the
immunohistochemical analysis showed that the tumor
was AFP-negative. Previous authors reported the occur-
rence of gastric adenocarcinoma with a high serum AFP
level and synchronous hepatic metastasis [12]. It has sub-
sequently become clear that there are two distinct histo-
logic subtypes: a medullary type and a papillary or
tubular type. The medullary type tends to stain more
strongly for AFP [12]. Our case showed moderately dif-
ferentiated tubular adenocarcinoma. Additionally, an
immunohistochemical analysis showed that the cells pre-
sent in the metastatic liver tumor and the gastric lesion
were AFP-negative. The regulation of gastric cancer cell
lines by hepatocyte growth factor (HGF) and c-metproto-
oncogene (c-Met) has been described recently [13]. HGF
is strongly associated with the progression of cancer cells
to invasive phenotypes and the development of distant
metastases. A higher incidence of c-Met overexpression
was found in AFP-secreting tumors, as well as a higher
expression in poorly differentiated tumors in the AFP-
positive group than in those that were AFP-negative [13].
A serum AFP level over 500 ng/mL in gastric cancer is
rare.
Studies have correlated levels of CA 72-4 with findings
of pathologic examinations in gastric carcinoma. These
have shown significantly higher marker levels associated
with gastric serosa invasion by the neoplasia and invasion
of veins or lymphatic vessels into the gastric wall as well as
lymph-nodal metastases [14]. A more advanced stage of
gastric cancer (stage III and IV) results in higher serum
levels of CA 72-4. Our patient had a normal CA 19-9
serum level. Elevated serum levels of CA 19-9 have been
described in 25% to 48% of patients with gastric cancers,
but these patients had multiple liver metastases. No corre-
lation was found between serum CA 19-9 level and the
stage of gastric cancer [15].
Conclusion
We have reported a rare gastric cancer in a patient with
NF-1 with high serum levels of multiple serum tumor
markers.
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